Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1983-1990

  Dürr, Stephan ^a   Lyer, Stefan ^a   Mann, Jenny ^a   Janko, Christina ^a   Tietze, Rainer ^a   Schreiber, Eveline ^a   Herrmann, Martin ^a   Alexiou, Christoph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cell culture; Magnetic drug targeting MCF 7 breast cancer cells; Magnetic nanoparticles; Real time cell analysis

Indexed keywords

LACTATE DEHYDROGENASE; MAGNETIC NANOPARTICLE; MITOXANTRONE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL VIABILITY; CYTOTOXICITY; DRUG TARGETING; HUMAN; HUMAN CELL; IMPEDANCE; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; REAL TIME CELL ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MAGNETICS; MALE; MITOXANTRONE; NANOPARTICLES; NEOPLASMS;

EID: 84861491149     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lauterwasser C (ed.). Small sizes that matter: Opportunities and Risks of Nanotechnologies. OECD/Allianz Group, München, 2005.
2. WHO: Cancer. Fact sheet No297, 2011, 〈www.who.int/ mediacentre/factsheets/fs297/en/index.html〉 (Last access: 30.08.2011).
3. Weiner LM: Fully human therapeutic monoclonal antibodies. J Immunother 29: 1-9, 2006.
4. Agarwal J, Palwe V, Dutta D, Gupta T, Laskar SG, Budrukkar A, Murthy V, Chaturvedi P, Pai P, Chaukar D, D'Cruz AK, Kulkarni S, Kulkarni A, Baccher G and Shrivastava SK: Objective assessment of swallowing function after definitive concurrent (chemo)radiotherapy in patients with head and neck cancer. Dysphagia 26: 399-406, 2011.
5. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S and Lübbe AS: Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60: 6641- 6648, 2000.
6. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E and Parak F: Magnetic drug targeting -Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11: 139-149, 2003. (Pubitemid 37236327)
7. Alexiou C, Schmid RJ, Jurgons R, Kremer M, Wanner G, Bergemann C, Huenges E, Nawroth T, Arnold W and Parak FG: Targeting cancer cells: magnetic nanoparticles as drug carriers. Eur Biophys J 35: 446-450, 2006.
8. Alexiou C, Jurgons R, Seliger C and Iro H: Medical applications of magnetic nanoparticles. J Nanosci Nanotechnol 6: 2762-2768, 2006. (Pubitemid 44579944)
9. Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H and Odenbach S: Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res 27: 2019-2022, 2007. (Pubitemid 46954718)
10. Lyer S, Tietze R, Jurgons R, Struffert T, Engelhorn T, Schreiber E, Dörfler A and Alexiou C: Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study. Anticancer Res 30: 1553-1557, 2010.
11. Hodenius M: Polymer- und liposomstabilisierte Ferrofluide und ihre Funktionalisierung. PhD thesis, Fakultät für Mathematik, Informatik und Naturwissenschaften RWTH Aachen, 2002.
12. Kapuscinski J, Darzynkiewicz Z, Traganos F and Melamed MR: Interactions of a new antitumour agent, 1,4-dihydroxy-5,8-bis [[2-[(2-hydroxyethyl)amino]- ethyl]amino]-9,10-anthracenedione, with nucleic acids. Biochem Pharmacol 30: 231-240, 1981. (Pubitemid 11210736)
13. Frank P and Novak RF: Mitoxantrone and bisantrene inhibition of platelet aggregation and prostaglandin E2 production in vitro. Biochem Pharmacol 34:3609-3614, 1985. (Pubitemid 16252547)
14. Roche Applied Science: 〈http://www.roche-applied-science.com/ sis/xcelligence/index.jsp?&id=xcect-000000〉(Last access: 30.08.2011).
15. Alexiou C, Tietze R, Schreiber E, Jurgons R, Richter H, Trahms L, Rahn H, Odenbach S and Lyer S: Cancer therapy with drug loaded magnetic nanoparticles - magnetic drug targeting. J Magn Magn Mater 323: 1404-1407, 2011.
16. Alberts DS, Griffith KS, Goodman GE, Herman TS and Murray E: Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. Cancer Chemother Pharmacol 5: 11-15, 1980. (Pubitemid 11194263)
17. Bese NS: Radiochemotherapy in the treatment of breast cancer. Clin Oncol (R Coll Radiol) 21: 532-535, 2009.
18. Garmey EG, Sartor O, Halabi S and Vogelzang NJ: Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 6: 118-122, 127-132, 2008.
19. Shepherd FA, Evans WK, Blackstein ME, Fine S, Heathcote J, Langer B, Taylor B, Habal F, Kutas G, Pritchard KI and Kuruvilla P: Hepatic arterial infusion of Mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol 5: 635-640, 1987. (Pubitemid 17062503)
20. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J and Weissleder R: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348: 2491-2499, 2003. (Pubitemid 36706536)
21. Taupitz M, Wagner S, Hamm B, Dienemann D, Lawaczeck R and Wolf KJ: MR lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumour model. Acta Radiol 34: 10-15, 1993. (Pubitemid 23079350)
22. Gao Y and Kumar C (ed.). Biofunctionalization of Nanomaterials. Vol 72. Wiley-VCH GmbH & Co. KGaA, Weinheim, 2005.
23. Storm G, Belliot SO, Daemen T and Lasic DD: Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliver Rev 17: 31- 48, 1995.
24. Hussain SM, Hess KL, Gearhart JM, Geiss KT and Schlager JJ: In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 19: 975-983, 2005. (Pubitemid 41563236)
25. Gupta AK and Gupta M: Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials 26: 1565-1573, 2005. (Pubitemid 39441388)
26. Haas TA and Plow EF: Integrin-ligand interactions: a year in review. Curr Opin Cell Biol 6: 656-662, 1994. (Pubitemid 24295298)
27. Roche Applied Science: The xCELLigence System - New Horizons in Cellular Analysis. Roche Diagnostics GmbH, Mannheim, 2008.